Biotech

All Articles

Kairos goes public with $6M IPO to finance tests of cancer cells medicine

.Along with a triad of biotechs striking the Nasdaq on Friday, it was actually very easy to skip a s...

Vaccine and Keytruda combination effective in squamous tissue cancer

.Invulnerable gate preventions are the superheroes of cancer cells treatment. Medicines like Bristol...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings as...

Regeneron's Opdualag competitor reveals 57% reaction cost

.Regeneron is back along with long-lasting consequence for its own LAG-3 prevention and also PD-1 in...

AstraZeneca posts information on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early check out the performance of its own internal antibody-drug con...

iTeos- GSK's TIGIT celebrity reveals relevant remodeling

.After announcing a phase 3 launch based upon beneficial midstage end results, iTeos as well as GSK ...

More collective FDA can accelerate uncommon health condition R&ampD: report

.The FDA must be actually a lot more open and collaborative to release a rise in approvals of rare c...

Zenas, MBX, Bicara scalp to Nasdaq in very hot day for biotech IPOs

.It's an extraordinarily hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bi...

Atea's COVID antiviral falls short to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has stopped working yet another COVID-19 test, yet the biotech stil...

Neurocrine's bid to spare mental illness prospect falls short

.Neurocrine Biosciences' mental illness system pivot has actually neglected. The biotech was actuall...